Mackenzie Financial Corp Boosts Position in Humana Inc. (NYSE:HUM)

Mackenzie Financial Corp increased its holdings in shares of Humana Inc. (NYSE:HUM) by 75.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 121,746 shares of the insurance provider’s stock after purchasing an additional 52,469 shares during the quarter. Mackenzie Financial Corp’s holdings in Humana were worth $55,737,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Cibc World Market Inc. raised its stake in shares of Humana by 4.0% in the first quarter. Cibc World Market Inc. now owns 5,709 shares of the insurance provider’s stock valued at $2,484,000 after acquiring an additional 217 shares in the last quarter. Blair William & Co. IL grew its holdings in shares of Humana by 0.6% during the first quarter. Blair William & Co. IL now owns 5,660 shares of the insurance provider’s stock worth $2,463,000 after buying an additional 32 shares during the last quarter. Cetera Investment Advisers grew its holdings in shares of Humana by 0.5% during the first quarter. Cetera Investment Advisers now owns 4,906 shares of the insurance provider’s stock worth $2,135,000 after buying an additional 26 shares during the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of Humana by 19.0% during the first quarter. Sequoia Financial Advisors LLC now owns 615 shares of the insurance provider’s stock worth $268,000 after buying an additional 98 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its position in Humana by 25.0% in the first quarter. Candriam Luxembourg S.C.A. now owns 29,809 shares of the insurance provider’s stock valued at $12,971,000 after purchasing an additional 5,964 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Performance

NYSE:HUM opened at $317.42 on Wednesday. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $38.30 billion, a price-to-earnings ratio of 16.02, a PEG ratio of 1.84 and a beta of 0.45. The firm’s fifty day simple moving average is $345.31 and its 200 day simple moving average is $426.43. Humana Inc. has a twelve month low of $299.23 and a twelve month high of $541.21.

Humana (NYSE:HUM) last posted its earnings results on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.87). Humana had a net margin of 2.34% and a return on equity of 19.44%. The business had revenue of $26.46 billion for the quarter, compared to analyst estimates of $25.47 billion. During the same quarter in the previous year, the firm posted $1.62 EPS. The business’s revenue was up 17.9% compared to the same quarter last year. As a group, equities research analysts expect that Humana Inc. will post 16.06 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Friday, March 29th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.12%. Humana’s dividend payout ratio (DPR) is presently 17.86%.

Insider Activity

In related news, Director Jorge S. Mesquita bought 545 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were acquired at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the purchase, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.29% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Barclays reduced their price objective on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 2nd. StockNews.com downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 26th. The Goldman Sachs Group reduced their price objective on shares of Humana from $450.00 to $385.00 and set a “buy” rating for the company in a research report on Wednesday, April 3rd. Truist Financial reiterated a “hold” rating and set a $550.00 price target on shares of Humana in a research report on Friday, January 19th. Finally, TD Cowen reduced their price target on shares of Humana from $427.00 to $396.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Eleven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $465.42.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.